74045-91-3

Basic information

• Product Name: 1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID HYDRAZIDE
• Synonyms: 1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID HYDRAZIDE;1-Benzylpiperidine-4-carbohydrazide
• CAS NO: 74045-91-3
• Molecular Formula: C₁₃H₁₉N₃O
• Molecular Weight: 233.31
• Mol File: 74045-91-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID HYDRAZIDE(74045-91-3)
• EPA Substance Registry System: 1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID HYDRAZIDE(74045-91-3)

Safety Data

• Hazardous Substances Data: 74045-91-3(Hazardous Substances Data)

Usage

General Description

1-Benzyl-piperidine-4-carboxylic acid hydrazide, also known as BPCHA hydrazide, is a compound with potential application in medicinal chemistry and drug development. It is a hydrazide derivative of the piperidine carboxylic acid, and it is used as a chemical intermediate in the synthesis of various pharmaceutical compounds. 1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID HYDRAZIDE has been studied for its potential use in the treatment of various diseases, including neurological and psychiatric disorders. Additionally, it has been explored for its potential as an anti-tuberculosis agent. Its unique chemical structure and potential biological activities make it an interesting target for further research and development in the field of medicinal chemistry.

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 24228-40-8 N-benzyl isonipecotic acid ethyl ester 

Downstream Products

• 1046079-80-4 1-benzyl-4-[1,3,4]oxadiazol-2-yl-piperidine 
• 50541-93-0 4-amino-1-benzylpiperidine 

Relevant articles and documents

Synthesis, bioactivity and molecular modeling studies on potential anti-Alzheimer piperidinehydrazide-hydrazones

A group of N-benzylpiperidine-3/4-carbohydrazide-hydrazones were designed, synthesized and evaluated for acetylcholinesterase (AChE), butyrylcholinesterase (BuChE)activities, Aβ42 self-aggregation inhibitory potentials, and antioxidant capacities, in vitro. All of the compounds displayed eeAChE and huAChE inhibitory activity in a range of IC50 = 5.68–11.35 μM and IC50 = 8.80–74.40 μM, respectively and most of the compounds exhibited good to moderate inhibitory activity on BuChE enzyme. Kinetic analysis and molecular modeling studies were also performed for the most potent compounds (1g and 1j). Not only the molecular modeling studies but also the kinetic analysis suggested that these compounds might be able to interact with the catalytic active site (CAS)and the peripheral anionic site (PAS)of the enzymes. In the light of the results, compound 1g and compound 1j may be suggested as lead compounds for multifunctional therapy of AD.